Cipla Q2 Results 2026: Net Profit Rises 3.8% YoY, Revenue Up 7.6% on Strong Global Demand; Share Price Down 4%

Pharma major Cipla Ltd on Thursday, October 30, reported a steady performance for the July-September quarter (Q2FY26), with growth across its domestic and international businesses. The company's consolidated net profit rose 3.8% year-on-year (YoY) to Rs 1,351 crore, compared to Rs 1,303 crore in the same period last year, aided by robust demand in India, steady U.S. sales and a strong showing in emerging markets and Europe.

Cipla Q2 Results 2026: Net Profit Rises 3.8% YoY, Revenue Up 7.6% Driven by India and Emerging Markets Growth

Cipla's consolidated revenue increased 7.6% YoY to Rs 7,589 crore, as against Rs 7,051 crore in the corresponding quarter of the previous year. The growth was largely driven by its India formulations business and double-digit expansion in emerging markets and European operations.

Cipla Q2 Earnings: EBITDA Rises Marginally

The company's earnings before interest, tax, depreciation and amortisation (EBITDA) rose marginally by 0.5% YoY to Rs 1,894 crore, compared to Rs 1,886.1 crore in the same quarter last year. However, EBITDA margin slipped to 25%, from 26.7% a year ago, indicating some moderation in profitability due to increased research and development (R&D) expenses and pricing pressure in select geographies.

Steady 7% Growth in Cipla's India Business

Cipla's India formulations business, which contributes the largest share to its revenue, grew 7% YoY to Rs 3,146 crore, in line with market expectations of 7%-9% growth. The company attributed the performance to continued strength in its respiratory, chronic, and branded prescription segments.

US and International Markets Drive Growth

In the U.S. market, Cipla delivered sales worth $233 million, maintaining stability despite ongoing pricing challenges in certain products such as gRevlimid. The performance was supported by steady contributions from complex generics and niche respiratory therapies.

The One Africa business posted 5% YoY growth, with sales rising to $134 million, backed by resilient demand across South Africa and other African regions. Meanwhile, the Emerging Markets and Europe segment recorded an impressive 15% YoY growth, with quarterly revenue reaching $110 million, the highest-ever quarterly revenue from this geography for Cipla.

Cipla Share Price Today Post Q2 Results Announcement

Shares of Cipla Ltd came under pressure on Wednesday, falling nearly 4% in afternoon trade following the company's September quarter (Q2FY26) earnings announcement. At 1:49 p.m., Cipla's stock was trading 3.95% lower at Rs 1,518.60, down Rs 62.50 from the previous close.

The stock opened at Rs 1,587.00 and touched an intraday high of Rs 1,593.30 in early trade before slipping to an intraday low of Rs 1,513.40 as investors reacted to the company's quarterly performance and margin pressures.